Which VEGF-inhibitor for neovascular AMD has the best return-on-investment?

Posted on

In this cost-benefit analysis, published clinical trial and Medicare data of 168,400 estimated patients in the United States with new-onset NVAMD in 2018 were analyzed to compare the societal cost-benefit of intravitreal bevacizumab, ranibizumab, and aflibercept monotherapies.


Individual 11-year cost: $14,772

Net societal return: $357,680


Individual 11-year cost: $106,582

Net societal return: $265,870


Individual 11-year cost: $61,811

Net societal return: $310,611

In the 2018 overall treatment cohort of patients with NVAMD, the 11-year net societal gain was $28.5 billion to patients and insurers. Approximately 85% ($24.2B) came from bevacizumab therapy, 2.5% ($0.7B) came from ranibizumab, and 12.6% ($3.6B) from aflibercept therapy.

An estimated $1.343 billion over 11 years would be saved if bevacizumab was substituted for ranibizumab and aflibercept in the 2018 patients with new-onset NVAMD.

The 11-year contribution to the Gross Domestic Product in 2018 dollars from vascular endothelial growth factor-inhibitor therapy for this cohort of patients was $12.2 billion.


Brown GC, Brown MM, Rapuano SB, et al. A cost-benefit analysis of VEGF-inhibitor therapy for neovascular age-related macular degeneration in the United States. Am J Ophthalmol. 2020; DOI:https://doi.org/10.1016/j.ajo.2020.07.010



Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021